Australia - English - Department of Health (Therapeutic Goods Administration)

thermo fisher scientific australia pty ltd - ct929 - acquired genetic alteration ivds - acquired genetic alteration control intended for use with next generation sequencing (ngs) assays that are designed to identify somatic mutations in dna from human samples. the control is intended to provide a means for assessing day-to-day test variation and may help in identifying increases in random or systematic error, such as reagent lot changes, operator-based deviations, and instrument malfunction.

Australia - English - Department of Health (Therapeutic Goods Administration)

abacus dx pty ltd - ct929 - acquired genetic alteration ivds - to be used in genetic testing to provide information about acquired genetic alterations

Australia - English - Department of Health (Therapeutic Goods Administration)

pegasus health group pty ltd - 38483 - pressure alleviation pad, air, alternating contact, - a pressure pad and a control unit, which is the pump, designed to distribute pressure between the patient and the contact surface over a large surface area by alternatively changing the pressure levels in the cells in the pressure pad. this reduces the pressure on the pressure points.

Australia - English - Department of Health (Therapeutic Goods Administration)

solari medical - 38483 - pressure alleviation pad, air, alternating contact, - a system consisting of a pressure pad and a control unit, which is also the pump, designed to distribute pressure between the patient and the contact surface, e.g. the bed or chair, over a large surface by alternatively changing the pressure levels in the cells in the pressure pad. this reduces pressure on the pressure points.

Australia - English - Department of Health (Therapeutic Goods Administration)

sysmex australia pty ltd - ct929 - acquired genetic alteration ivds - ivds that are intended to be used in genetic testing to provide information about acquired genetic alterations, which may include chromosomal alterations, mutations and/or alterations in gene expression, and which may be used to characterise haematological or solid tumour malignancies and/or provide prognostic information. these products are intended for use as an adjunct to classic cytogenetics and not as independent tests or assays.

Australia - English - Department of Health (Therapeutic Goods Administration)

alrick manufacturing & imports - 36688 - pressure alleviation pad, air, alternating contact, control unit - an air pump intended to provide the pressure required to fill and maintain an alternating pressure mattress

Australia - English - Department of Health (Therapeutic Goods Administration)

k care healthcare solutions pty ltd - 38483 - pressure alleviation pad, air, alternating contact, - an alternating therapy mattress overlay system designed to facilitate blood circulation and provide maximum body tissue redistribution for treating and prevention of pressure ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

k care healthcare solutions pty ltd - 38483 - pressure alleviation pad, air, alternating contact, - an alternating therapy mattress replacement system designed to facilitate blood circulation and provide maximum body tissue redistribution for treating and prevention of pressure ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

alrick manufacturing & imports - 38483 - pressure alleviation pad, air, alternating contact, - an alternating air mattress intended to distribute pressure in alternating cycles.

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - rumex acetosella pollen (unii: n52miq81zw) (rumex acetosella pollen - unii:n52miq81zw), rumex crispus pollen (unii: v825xjg64g) (rumex crispus pollen - unii:v825xjg64g) - alternaria alternata 0.1 g in 1 ml - these products are for diagnostic use only. diagnostic allergenic extracts are indicated for use in skin testing to establish the clinical relevance of specific allergens to which the patient has been exposed. by measuring skin test response, the physician may assess the degree of sensitivity that patients have to the allergens. for extracts standardized in au and bau, see individual directions for use. allergenic extracts for diagnostic use only of coffee, mosquito, cottonseed, and flaxseed have not been shown by adequate data to be safe and effective for therapeutic use. patients on beta blockers can be non-responsive to beta agonists that may be required to reverse a systemic reaction (also, see boxed warning statement and adverse reactions ). the physician should carefully weigh the benefit derived from skin testing vs. the risk to the patient should a systemic reaction arise. patients with unstable asthma or steroid dependent asthmatics and patients with underlying cardiovascular disease are at greater